Next 10 |
home / stock / acb / acb articles
Analyst Lorimer Wilson, a contributor at TalkMarkets, signaled that Canadian Limited Partnership (LPs) Cannabis Companies did much better than Amer...
President Joe Biden's shaky debate performance this week is stirring doubts among Democrats about his viability for reelection. As doubts&...
Aurora Cannabis (NASDAQ: ACB), a key player in the global medical marijuana market, stands at a strategic crossroads. Pablo Zuanic, a seasoned mari...
Aurora Cannabis Inc. (NASDAQ:ACB) (TSX:ACB) announced its financial and operational results Thursday for the fourth quarter and fiscal year 2024. T...
A short squeeze forces investors betting on a stock's decline (short sellers) to buy back shares at a higher price to avoid losses, triggering ...
The medical cannabis packaging market is undergoing rapid expansion, forecasted to catapult from $6.5 billion in 2023 to a staggering $117.2 billio...
Lawmakers in Germany have set a maximum allowed limit of THC – the psychoactive substance found in the cannabis plant – for drivers to have...
Canadian cannabis giant Aurora Cannabis Inc.(NASDAQ:ACB) (TSX:ACB) in conjunction with MedReleaf Australia, is launching its premium 1.2g resin car...
As the 19th Benzinga Cannabis Capital Conference returns to Chicago (Oct. 8-9), gathering top CEOs, investors and leaders in the marijuana industry...
News, Short Squeeze, Breakout and More Instantly...
--News Direct-- When it comes to investing in the legal marijuana industry, they don't call it the "green rush" for nothing. Many analysts are projecting massive growth for the cannabis industry. New Frontier, a Washington D.C.-based cannabis research firm, expects total U.S. legal cannabis s...
2024-07-18 05:30:00 ET To say Aurora Cannabis (NASDAQ: ACB) has faced some challenges over the years would be a huge understatement. The once-leading cannabis producer in the Canadian marijuana industry is now a shell of its former self. Instead of acquiring large cannabis compani...
The marijuana industry has been significantly hindered by Section 280E of the IRS Code , which prevents businesses dealing with substances listed in Schedules 1 and 2 of the Controlled Substances Act (CSA) from deducting regular business expenses. Although Section 280E affects federal deductio...